Skip to main content
OpenTrials
Completed

NCT Number: NCT02111681

Calypso-based Deep Inspiration Breath Hold (DIBH) Radiation Treatments of Lung Cancer

The purpose of this study is to test the use of Calypso beacon implants as a way to determine where the lung tumor is located during radiation treatment. The Calypso beacons are small devices that are implanted in the lungs, near the tumor. They are able to send a signal to a tracking system to show where they are, and where the tumor is, as the patient holds their breath for the radiation treatment. The investigators want to find out what effects, good and/or bad, that this has on the patient and the way they treat the cancer in your lungs.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients must have histologic proof of malignancy suitable for thoracic radiation therapy
  • Patients planning to undergo radiation therapy for primary or recurrent malignancy of the lung or metastatic malignancy to the lung.
  • Age ≥ 18 years old
  • KPS ≥ 60%
  • Ability to hold their breath for >20 seconds for 5 times
  • Patients who are able to tolerate flexible bronchoscopy
  • Patients with life expectancy of at least 12 months
  • Patients able to have bronchoscopic placement of Calypso as confirmed on a recent (within the past 8 weeks) CT scan.
  • Patients who are able to comply with the protocol follow-up schedule.

Exclusion criteria

  • Patients unable to comply with instructions for DIBH
  • Patients with implants in the chest region that contain metal or conductive materials (e.g., metal implants, rods, or plates) which Calypso Medical considers will interfere with the Calypso System's electromagnetic localization.
  • Patients with active implanted devices, such as pacemakers, defibrillators, and drug infusion pumps since the effects of the Calypso System operation on these devices are unknown.
  • Patients with clinically significant active infections.
  • Patients with bronchiectasis in the region of the intended implantation sites.
  • Patients with a history of hypersensitivity to nickel.
  • Patients whose lung tumors are being monitored with MR imaging (MR imaging of the anchored transponders is safe but yields an image artifact around the anchored transponders).
  • Posterior lesions that would be >19cm distance from Calypso detector plate. Patients may be treated in the prone position in order to meet the required minimum distance.
  • Patients with any other medical condition or laboratory value that would, at the discretion of the investigator, preclude the patient from participation in this clinical study.
  • Patients who are deemed unable to safely undergo or tolerate flexible bronchoscopy
  • Patients who are unable to tolerate anesthesia or sedation
  • Patients enrolled in any other clinical studies the investigator believes to be in conflict with this investigation.
  • Female patients who are pregnant or nursing

Treatment and study plan

Calypso Beacon Implantation

Device

Bronchoscopic Calypso Beacon Implantation

Primary outcomes

  1. Feasibility of Calypso Transponders

    Time frame: 2 years

    Feasibility is defined as completion of all treatments using the DIBH treatment plan and Calypso transponders.

Secondary outcomes

  1. Reproducibility

    Time frame: 2 years

    We will compare the visual vs no visual biofeedback treatments (done for each patient) by the number of treatment interruptions.

  2. Measure the Residual Intrafraction Tumor Motion

    Time frame: 2 years

    will be measured in all 3 dimensions and the euclidean distance will be calculated in milimeters/mm, which will then be correlated with the normal tissue dosimetry by regression analysis.

Sponsors and collaborators

Lead sponsor

Memorial Sloan Kettering Cancer Center

Other

Collaborators

  • Varian Medical Systems

Registry information

Important dates

Study start
2014
Primary completion
2024
Study completion
2024
First posted
Apr 11, 2014
Registry last updated
Sep 26, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.